9, RUE DE BITBOURG, LUXEMBOURG, N4
Announces FDA Acceptance for Review of Biologics License Application for AVT80, Expanding Proposed Biosimilar Program for Entyvio® to Subcutaneous Presentations
Announces Licensing and Commercialization Agreement for Proposed Biosimilars to Durvalumab and Emicizumab in the U.S. and Selected Asian Markets
Announces Financial Results for the First Half of 2026 and Provides a Business Update
Material disclosure
Secures Additional Term Loan Facility of $75 Million
Announces Closing of Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares, Raising an Aggregate of $165 Million with Concurrent Private Placement
Announces Pricing of $152 Million Public Offering of Ordinary Shares and Concurrent Private Placement
Annual and Transition Report of Foreign Private Issuers
Prospectus filed pursuant to Rule 424(b)(5)
Prospectus filed pursuant to Rule 424(b)(3)
Effectiveness Notice
Registration Statement for Securities of Certain Foreign Private Issuers and Certain Canadian Issuers, Offered on a Continuous Basis
RW
No filings found
Amended Schedule 13D - Ownership Report
Amended Schedule 13G - Ownership Report
Schedule 13G - Ownership Report
Free Writing Prospectus
Submission Upload
Correspondence
Automatic Shelf Registration Statement for Securities of Certain Foreign Private Issuers and Certain Canadian Issuers, Offered on a Continuous Basis